Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease (Q34075182)

30 July 2017

1 reference

title

Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease (English)

1 reference

30 July 2017

Sunder-Plassmann G

1

1 reference

30 July 2017

Winkelmayer WC

series ordinal

2

1 reference

30 July 2017

Födinger M

series ordinal

3

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 November 2000

1 reference

Expert Opinion on Investigational Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

9

1 reference

30 July 2017

issue

11

1 reference

30 July 2017

page(s)

2637-2651

1 reference

Homocysteine and vascular disease

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Homocysteine and its disulfide derivatives: a suggested consensus terminology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

No net renal extraction of homocysteine in fasting humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Homocysteine and methionine metabolism in ESRD: A stable isotope study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Acute hyperinsulinemia reduces plasma concentrations of homocysteine in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Molecular basis for methionine synthase reductase deficiency in patients belonging to the cblE complementation group of disorders in folate/cobalamin metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Recent data are not in conflict with homocysteine as a cardiovascular risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Major determinants of hyperhomocysteinemia in peritoneal dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Serum methylmalonic acid in uraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Hypomethylation as a cause of homocysteine-induced cell damage in human cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

A common mutation in the methylenetetrahydrofolate reductase gene and risk of coronary heart disease: results among U.S. men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Oral folate enhances endothelial function in hyperhomocysteinaemic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

The effect of different treatment regimens in reducing fasting and postmethionine-load homocysteine concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

High prevalence of hyperhomocysteinemia in critically ill patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease patients after fortification of cereal grain flour with folic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Molecular genetics of homocysteine metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Treatment with different doses of folic acid in haemodialysis patients: effects on folate distribution and aminothiol concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

Influence of Folic Acid on Postprandial Endothelial Dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

5-Methyltetrahydrofolate, the Active Form of Folic Acid, Restores Endothelial Function in Familial Hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2637

10.1517/13543784.9.11.2637

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference